Interface between Regulation and Statistics in Drug Development

Author:   Demissie Alemayehu ,  Birol Emir ,  Michael Gaffney (Pfizer Inc., New York)
Publisher:   Taylor & Francis Ltd
ISBN:  

9780367608286


Pages:   146
Publication Date:   01 August 2022
Format:   Paperback
Availability:   In Print   Availability explained
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.

Our Price $96.99 Quantity:  
Add to Cart

Share |

Interface between Regulation and Statistics in Drug Development


Add your own review!

Overview

Full Product Details

Author:   Demissie Alemayehu ,  Birol Emir ,  Michael Gaffney (Pfizer Inc., New York)
Publisher:   Taylor & Francis Ltd
Imprint:   Chapman & Hall/CRC
Weight:   0.249kg
ISBN:  

9780367608286


ISBN 10:   0367608286
Pages:   146
Publication Date:   01 August 2022
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   In Print   Availability explained
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.

Table of Contents

Reviews

Author Information

Demissie Alemayehu, PhD, is Vice President and Head of the Statistical Research and Data Science Center at Pfizer Inc. He is a Fellow of the American Statistical Association, has published widely, and has served on the editorial boards of major journals, including the ""Journal of the American Statistical Association"" and the ""Journal of Nonparametric Statistics."" Additionally, he has been on the faculties of both Columbia University and Western Michigan University. He has co-authored a monograph entitled, ""Patient-Reported Outcomes: Measurement, Implementation and Interpretation,"" and co-edited another, ""Statistical Topics in Health Economics and Outcome Research"" both published by Chapman & Hall/CRC Press. Birol Emir, PhD, is Senior Director and Statistics Lead of Real-World Evidence (RWE) at Pfizer Inc. In addition, Dr. Emir has served as Adjunct Professor of Statistics and Lecturer at Columbia University in New York and as an External PhD Committee Member, Graduate School of Arts and Sciences, Rutgers, The State University of New Jersey. Recently, his primary focuses have been on big data, predictive modelling and genomic data analysis. He has numerous publications in refereed journals, and he has co-edited ""Statistical Topics in Health Economics and Outcome Research"" published by Chapman & Hall/CRC Press. He has taught many short courses and has given several invited presentations. Michael Gaffney, PhD, is Vice President, Statistics at Pfizer, and received his Ph.D. from New York University School of Environmental Medicine with his dissertation in the area of multistage model of cancer induction. Dr. Gaffney has spent his 43-year career in pharmaceutical research concentrating in the areas of design and analysis of clinical trials and regulatory interaction for drug approval and product defense. He has interacted with FDA, EMA, MHRA and regulators in Canada and Japan on over 25 distinct regulatory approvals and product issues in many therapeutic areas. Dr. Gaffney has published 40 peer-reviewed articles and presented at numerous scientific meetings in diverse areas of modelling cancer induction, variance components, harmonic regression, factor analysis, propensity scores, meta-analysis, large safety trials and sample size re-estimation. Dr. Gaffney was recently a member of the Council for International Organizations of Medical Sciences (CIOMS) X committee and was a co-author of, CIOMS X: Evidence Synthesis and Meta-Analysis for Drug Safety.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions
Latest Reading Guide

MRG2025CC

 

Shopping Cart
Your cart is empty
Shopping cart
Mailing List